← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mabvax Therapeutics, Inc.
San Diego, CA
$5,381,699
Total funding
6
Grants
Funding over time
peak $1.5M · FY2007–14$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$5,381,699 · 6
By mechanism
R44$1,978,841 · 1
N01$1,749,399 · 1
R42$1,104,717 · 1
R41$399,590 · 2
R43$149,152 · 1
Investigators at Mabvax Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Contract Title: SBIR Phase I Topic 324 Development of an Imaging Agent Targeting$1,499,434
N01 · FY2014 · CA
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect$973,936
R44 · FY2011 · CA
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect$854,905
R44 · FY2012 · CA
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien$569,051
R42 · FY2011 · CA
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien$535,666
R42 · FY2010 · CA
Contract Title: SBIR Phase I Topic 324 Development of an Imaging Agent Targeting$249,965
N43 · FY2013 · CA
Pilot trial with a tetravalent conjugate vaccine against small cell lung cancer$201,826
R41 · FY2007 · CA
Human Monoclonal Antibodies from Immunized Patient Lymphocytes$197,764
R41 · FY2008 · CA
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect$150,000
R44 · FY2010 · CA
CONSTRUCTION AND TESTING OF A TRIVALENT VACCINE AGAINST NEUROBLASTOMA ADMINISTERE$149,152
R43 · FY2012 · CA